10x Genomics, Inc.·4

Apr 16, 4:07 PM ET

Saxonov Serge 4

4 · 10x Genomics, Inc. · Filed Apr 16, 2026

Research Summary

AI-generated summary of this filing

Updated

10x Genomics (TXG) CEO Serge Saxonov Sells 5,000 Shares

What Happened

  • Serge Saxonov, CEO of 10x Genomics, reported an open-market sale of 5,000 shares on April 14, 2026. The weighted average sale price was $24.56, with trade prices ranging from $24.49 to $24.70, for total proceeds of approximately $122,784. This was a sale (not a purchase), and such transactions are commonly routine dispositions.

Key Details

  • Transaction date: 2026-04-14 (reported on Form 4 filed 2026-04-16)
  • Transaction type/code: Open-market sale (S)
  • Shares sold: 5,000; weighted average price: $24.56; price range: $24.49–$24.70; proceeds ≈ $122,784
  • Ownership after transaction: Not specified in the provided filing excerpt
  • Notable footnotes:
    • F1: Sale executed pursuant to a Rule 10b5-1 trading plan adopted Nov 29, 2025
    • F2: Multiple trades; Reporting Person can provide breakdown of shares sold at each price on request
    • F3–F5: Some shares referenced are held in trusts (Andromeda Trust, Y/S Descendants' Trust, Y/S Pot Trust) for which Saxonov serves as trustee
  • Timeliness: Filed within the typical two-business-day window (not indicated as late)

Context

  • The sale was executed under a pre-established 10b5-1 plan, which is designed to allow insiders to sell shares according to a predetermined schedule and reduce concerns about trading on inside information. Sales are generally less informative than purchases about an insider’s view of the company; this entry documents a routine disposition rather than an acquisition.

Insider Transaction Report

Form 4
Period: 2026-04-14
Saxonov Serge
DirectorChief Executive Officer
Transactions
  • Sale

    Class A Common Stock

    [F1][F2]
    2026-04-14$24.56/sh5,000$122,7841,167,273 total
Holdings
  • Class A Common Stock

    [F3]
    (indirect: See footnote)
    27
  • Class A Common Stock

    [F4]
    (indirect: See footnote)
    213,250
  • Class A Common Stock

    [F5]
    (indirect: See footnote)
    71,644
Footnotes (5)
  • [F1]The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
  • [F2]This transaction was executed in multiple trades at prices ranging from $24.49 to $24.70, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F3]The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
  • [F4]The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
  • [F5]The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
Signature
/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov|2026-04-16

Documents

1 file
  • 4
    form4.xmlPrimary